In spite of an effort to harmonize the latest editions of International Classification of Dis eases (ICD) and Diagnostic and Statistical Manual (DSM), a number of differences between the two classification systems still exist. One of these differences is related to the category of somatoform dis orders. The cross-cultural applicability of ICD-10 and DSM-IV criteria for somatoform disorders have been explored in the context of the ongoing WHO International Study of Somatoform Disorders. The study demonstrated that the current diagnostic concepts of somatoform disorders are cross-culturally acceptable in spite of the differences in their descriptions and classifications. However, it was found that a number of culture specific symptoms of somatoform disorders which do not appear in ICD-10 and DSM-IV were important and necessary for their diagnosis in specific cultures. (Keio J Med 46 (3): 128-131, September 1997) 
Introduction
Psychological problems presenting as somatic symp toms are a frequent reason worldwide for contact with health services. Somatoform disorders and neurasthe nia constitute an important component of this psycho logical morbidity in both developed and developing countries.1 These disorders produce substantial levels of disability and results in repeated use of health ser vices. In response to the major public health problems posed by these disorders, the World Health Organiza tion (WHO) has recently launched an international study of somatoform disorders in different cultures.2 A major specific goal of this study is to test the cross cultural applicability of the symptoms and criteria for somatoform disorders in the tenth revision of the International Classification of Diseases (ICD-10) of WHO3 and the fourth edition of the Diagnostic and Statistical Manual (DSM-IV) of the American Psychi atric Association. 4 Both ICD-10 and DSM-IV have recognized the use fulness of a broad category of 'somatoform disorders'.
However, different organizing principles have been used by these two classifications to bring together several dis orders with predominantly physical or somatic modes of presentation. Substantial differences continue to exist between the two systems.5,6 Pseudoneurologic (con version) symptoms, which include paralysis , amnesia, loss of consciousness and hallucinations, are part of the criteria for somatization disorder in DSM-IV, unlike in ICD-10. Symptoms involving the autonomic system are included in ICD-10 under the category of somatoform autonomic dysfunction. ICD-10 also includes 'neuras thenia', since this diagnosis is still regularly and widely used in a number of countries, but it does not appear in DSM-IV. There is a need for empirical research to support the comparative validity of many of the soma toform disorders categories.
As a preliminary step in the WHO International Study of Somatoform Disorders , a mail questionnaire survey was organized to obtain the opinions of experts from different cultures on the ICD-10 definitions of somatoform disorders and the specific characteristics of the symptoms related to these conditions .' The results of the survey revealed that the ICD-10 concept of somatoform disorders is generally acceptable for use across cultures.
During Phase I of this study, the Somatoform Dis orders Schedule (SDS)8 was developed and field-tested for its reliability and cross-cultural applicability in Bra zil, India, Italy, the USA and Zimbabwe.9 This paper is based on the results from Phase I of the study and reports the relative frequencies of various somatic symptoms and their relevance for diagnosis of somato form disorders according to ICD-10 and DSM-IV.
Methods
The The patients for the study were recruited from pri mary care, general medical and psychiatric outpatient settings. A 12-item screening questionnaire for somato form disorders" was administered to all those who agreed to participate in the study. Patients with three or more positive somatic symptoms lasting three or more months and not explained by physical illness, injury, alcohol or drug use were assessed in detail using the Somatoform Disorders Schedule (SDS). The SDS is a highly standardized diagnostic instrument designed for the assessment of somatoform disorders according to ICD-10 and DSM-IV criteria and intended for epi demiologic and comparative research on somatoform disorders in different cultures and settings. The instru ment has a brief section on demographics and a symp tom summary section which comprises questions on variations in symptoms, care-seeking behaviour, type and effectiveness of treatment and satisfaction with care. The clinical significance of positive answers to SDS symptom questions is explored by a clearly speci fied probing system. A symptom was rated positive and psychiatrically relevant when it led to professional con sultation, treatment with medication or was believed by the patient to have interfered significantly with life or activities, and the patient reported that there was at least one occasion when its occurrence was not explained by physical illness, injury or substance use.
Alternatively, a physician attributed a psychological causation to the symptom and found no physical basis for it. SDS was translated and back-translated, follow ing WHO guidelines for the translation of assessment instruments into Kannada, Italian, Shona and Portu guese at the centres in India, Italy, Zimbabwe and Brazil, respectively. At each of the participating centres, the investigators were trained in the administration of SDS and completed five test interviews before the data collection. The analysis of data for this paper consists of the calculation of frequencies of positive and psychiatrically relevant symptoms from the SDS and the content anal ysis of participating centres' reports. In addition, each symptom was assigned to one of the following four categories: pain, gastrointestinal, cardiopulmonary and conversion (dissociative symptoms). Within each of these groups, the frequency of symptoms was ranked from most common to least common and analysis of variance was used to determine which symptoms were significantly more common.
Results
Selected sociodemographic characteristics of the sample of 180 patients assessed at all five sites are given in Table 1 . The majority (75%) were females with a mean age of 42 years, and 59% were married at the time. The mean education level was 7-6 years of schooling and only 42% of the patients were employed. Table 2 shows the frequency of positive somatic symptoms grouped according to their relevance for diagnosis of somatoform disorders according to ICD-10 and DSM-IV.
Pains in different parts of the body such as the head, back, arms, legs and elsewhere, and certain gastro intestinal symptoms such as bloating, nausea, diarrhoea and vomiting required for a diagnosis of somatization disorder by both ICD-10 and DSM-IV were amongst the most prevalent symptoms at all sites. Conversion (pseudoneurologic) symptoms required by DSM-IV were infrequently reported. Using Scheffe's test at the alpha equal to 0.05 level, there was a significant differ ence between the frequency of pain symptoms and con version (pseudoneurological) symptoms. Autonomic symptoms such as palpitation, butterflies in the stom ach, hot/cold sweats, dry mouth and certain symp toms listed in ICD-10, such as a bad taste in the mouth, tingling and numbness, and breathlessness without exertion, were also reported quite frequently. Table 3 compares the most frequently reported somatic symptoms at all centres with the symptoms nominated as most useful for a diagnosis of somatoform disorders by a panel of international experts from dif ferent cultures. Various conversion (pseudoneurological) symptoms constitute one of the symptom-groupings in DSM-IV criteria for somatization disorder. But ICD-10 includes these symptoms under a separate category of "dis sociative (conversion) disorders" and does not require their presence for a diagnosis of somatization disorder. The relative infrequency of conversion symptoms at all centres makes diagnosis of somatization disorder according to DSM-IV very restrictive . The frequencies of various symptoms indicate that the ICD-10 grouping of somatization symptoms is perhaps more appropriate . The prevalence of a variety of autonomic symptoms at all centres indicates the usefulness of inclusion in ICD 10 of the category of somatoform autonomic dysfunc tion. Recently, various symptoms of tiredness , exhaus The analysis of the responses to the symptom sum mary section of the SDS revealed that 84% of patients reported some improvement in their symptoms as a re sponse to some form or other of treatment and 70% of patients were satisfied with the treatment. In addition, 55% of patients reported that their symptoms had remained the same, without much variation. There is a need to develop specific operational criteria for undif ferentiated somatoform disorder, which currently is a residual category in both classifications. Subthreshold categories are known to be widely prevalent in primary health care settings.
The content analysis of participating centres' reports showed that certain symptoms were inappropriate in some of the centres. For example, while symptoms such as blotchiness or discolouration of skin and flushing or blushing were not relevant in India and Zimbabwe, symptoms such as belching or hiccoughs were not reported in the USA. Some of the symptoms posed translation difficulties. For example, it was difficult for patients in India to distinguish between fainting, sei zures and unconsciousness in the Kannada translation of the SDS. In Kannada, the translated word for amnesia was mistaken by many patients for forgetfulness or loss of memory.
It is interesting to note that seven of the ten most frequent symptoms reported at all centres (namely headache, pain in limbs, back pain, chest pain, pain in joints, belly pain and bloating or excessive gas) are amongst the ten symptoms reported as "most useful" for identification of somatization by experts in the fields of cross-cultural psychiatry, psychology, anthropology and primary care from different cultures.
Phase II of the WHO International Study of Soma toform Disorders is currently underway in the following ten countries: Brazil, Bulgaria, China, Germany, India, Italy, Japan, the UK, the USA and Zimbabwe. The main goals of this phase of the project are to assess the prevalence and characteristics of somatoform disorders in different parts of the world and to develop and eval uate a management strategy for these disorders.
